Status: Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.
Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Pulmotect, Inc.Updated: Apr 24, 2026Locations: 11
Eligibility criteria
Subjects with hematologic malignancies (i.e., leukemia, lymphoma, or multiple my... [+12]
Patients with a pulse oximetry of hemoglobin saturation less than 93% on room ai... [+12]